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Strengths and limitations of this study
 ► This is the first systematic review and meta-analysis 
assessing the effectiveness of botanical fermented 
foods (BFFs) for adults with type 2 diabetes mellitus, 
metabolic syndrome and its components.
 ► To ensure highest quality scientific data, the conduct 
of this review will adhere to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses 
statement.
 ► Robust systematic methodology used to identify 
quality evidence will assist in elucidating wheth-
er BFFs are effective prevention and management 
tools for non-communicable metabolic diseases.
 ► This systematic review and meta-analysis will have 
inherent limitations related to included studies such 
as risk of bias, methodological inconsistencies and 
incomplete outcome data.
 ► Result interpretation may be affected by significant 
heterogeneity due to the vast differences between 
BFFs, trial administration issues and the variety of 
outcome measures.
AbStrACt
Introduction Dysfunctional gut microbiota is a common 
finding in patients with metabolic syndrome (MetS) and 
type 2 diabetes mellitus (T2DM). Recent clinical trials have 
assessed whether botanical fermented foods (BFFs) have 
beneficial effects on metabolic biomarkers, inflammatory 
markers and gut microbiota. The aim of this review is to 
critically evaluate all randomised controlled trials (RCTs) of 
BFF for evidence of impact on the outcome measures of 
these disease states.
Methods and analysis Four electronic databases 
(Embase, MEDLINE, CENTRAL and Google Scholar) 
as well as the grey literature will be searched from 
inception to present without language or publication 
status restrictions applied. Eligible RCTs which have 
enrolled adult participants with T2DM, any MetS 
components or combinations of these components, treated 
prophylactically or therapeutically with any botanical 
fermented food intervention, compared with a control 
group (no intervention, placebo or active control) will be 
assessed. Primary outcomes are related to the target 
conditions, including metabolic biomarkers, inflammatory 
markers and gut microbiota composition/function. Using 
Covidence, two independent investigators will conduct title 
and abstract screening, followed by full-text screening 
to identify appropriate studies. Methodological quality 
of the trials will be assessed using the Cochrane risk of 
bias assessment tool. Findings will be summarised with 
a narrative synthesis of the differences between included 
studies. A meta-analysis will be conducted if sufficient 
data are obtained.
Ethics and dissemination Ethical approval is not 
required as primary data will not be collected. Results 
will be disseminated through peer-reviewed publication, 
conference presentations and press.
PrOSPErO registration number CRD42018117766
IntrOduCtIOn
Diet alters the structure and activity of 
human gut microbiota,1 with direct effects 
on host health.2 Shifts in gut microbiota have 
been linked to host metabolism dysfunction 
and low-grade chronic inflammation; these 
disorders of metabolism are implicated 
in the development of obesity, metabolic 
syndrome (MetS) and type 2 diabetes mellitus 
(T2DM).3–5 MetS affects >25% of all adults 
globally6; T2DM is the world’s most prevalent 
endocrine disorder.5 As such, cheap, effec-
tive dietary therapies are of great interest 
to researchers, clinicians and government 
bodies.
Fermented products of plant origin, or 
botanical fermented foods (BFFs), are a 
microbially diverse part of global tradi-
tional diets.7 These indigenous traditional 
fermented foods (eg, kimchi, sauerkraut, 
tibicos, tempeh, miso, kombucha, natto 
and fermented olives), as well as newer 
functional fermented products such as red 
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Table 1 Inclusion and exclusion criteria
Criteria Inclusion criteria Exclusion criteria
Population Adults over 18 years old.
Diagnosed with T2DM, or suffering from any MetS 
components or combinations of these components.
Children.
Non-T2DM individuals. Healthy subjects not 
suffering from any MetS components.
Intervention BFFs and beverages.
May contain any concentration of any types of live 
microorganisms, or no live microorganisms at time of 
consumption.
Sole intervention.
Single compound extracts.
BFFs mixed with non-fermented ingredients.
BFFs as part of whole diet interventions.
Coffee, tea, chocolate, beer, wine, high alcoholic 
beverages.
Comparator Placebo, no intervention or active control groups. Any other type of intervention or comparison.
Outcome Related to target conditions (T2DM, MetS).
Changes in anthropometric measurements, blood 
pressure, lipid profile, glucose metabolism/glycaemic 
control, inflammatory markers, gut microbiota 
composition and metabolites.Others: liver markers, 
quality of life, mental health scales, adverse events.
Not related to target conditions.
Study design All clinical randomised controlled trials. All other study designs.
Language All languages. None.
Setting All settings. None.
BFFs, botanical fermented foods; MetS, metabolic syndrome; T2DM, type 2 diabetes mellitus.
yeast rice and functional kimchi, have been recognised 
as having beneficial effects on human health.8 9 The 
diversity of such ferments and their ingredients means 
they are abundant in microbiota-accessible carbohy-
drates, food-associated microorganisms such as lactic 
acid bacteria, bacterial components and metabolites, 
bioactive compounds such as polyphenols, vitamins and 
minerals.9 10 Besides the basic nutritional properties of 
BFF ingredients, fermentation itself may confer addi-
tional health benefits through interactions between the 
host and consumed live microorganisms (probiotics), or 
through the ingestion of food-associated microbe-pro-
duced metabolites (biogenics) and other products of 
fermentation.11 These include secondary phytochem-
icals, bioactive peptides and other compounds which 
have been shown to affect blood pressure, immune 
responses, antioxidant activity, insulin sensitivity, fasting 
and postprandial blood glucose.12 The action of human 
gut microbiota on fermented food components in 
the intestinal lumen also produces health-promoting 
compounds, such as fermentation of microbiota-acces-
sible carbohydrates into short chain fatty acids.8 Though 
relatively sparse compared with studies on fermented 
dairy products for human health, recent clinical trials of 
BFF support their role in the prevention and treatment 
of non-communicable chronic diseases,9 including 
obesity, pre-diabetes, type 2 diabetes, lipid dysfunction, 
cardiovascular disease, inflammatory bowel disorders 
and mental health disorders.8
Although a recent review of BFF in relation to non-com-
municable diseases has been conducted,9 as well as others 
critically reviewing the health benefits of fermented 
foods,8 no systematic review of the impact of BFF on MetS 
and T2DM has been undertaken. The aim is to system-
atically review randomised controlled trials (RCTs) for 
evidence of the impact of BFF compared with control on 
gut microbiota and metabolic biomarkers in adult human 
subjects suffering from components of MetS or T2DM. If 
sufficient homogeneous studies are identified, meta-anal-
ysis of the pooled data from these trials will elucidate the 
overall effect.
MEthOdS
Eligibility criteria
The Population, Intervention, Comparison, Outcome, 
Study type (PICOS) acronym13 was used in the determina-
tion of the inclusion and exclusion criteria for this review. 
We will select RCTs (S) investigating the impact of BFFs 
(I), compared with placebo, no intervention or active 
controls (C), on adults (P) with T2DM or MetS compo-
nents, or any combination of these components (O). 
Inclusion and exclusion criteria are shown in table 1.
Types of studies
All human RCTs in any language will be included.
Types of participants
This review will include trials with adult participants 
suffering from T2DM, or any MetS components or combi-
nations of these components (eg, obesity, hypertension, 
lipid dysfunction, glucose intolerance/pre-diabetes, 
non-alcoholic fatty liver disease).
Types of interventions and comparators
This review will include studies that evaluate tradi-
tional BFF (eg, kimchi, sauerkraut, tibicos, tempeh, 
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box 1 draft search strategy for Medline
1. randomised controlled trial.pt.
2. controlled clinical trial.pt.
3. (randomized or randomised).ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. exp animals/not humans.sh.
11. 9 not 10
12. Metabolic Syndrome/
13. diabetes mellitus, type 2/or diabetes mellitus, lipoatrophic/
14. Hypertension/
15. Insulin Resistance/
16. INSULIN/
17. Blood Glucose/
18. blood pressure/
19. cholesterol, HDL/
20. cholesterol, LDL/
21. Non-alcoholic Fatty Liver Disease/
22. Dyslipidemias/
23. PREDIABETIC STATE/
24. obesity/ or obesity, abdominal/ or obesity, morbid/
25. overweight/
26. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 
23 or 24 or 25
27. (metabolic syndrome* or metabolic disorder* or MetS or dyslipi-
demia* or dysglycemia* or hypertension or diabetes or prediabetes 
or neo diabetic or obesity or overweight or insulin or hyperlipidem-
ia* or lipid or blood pressure or NAFLD or non-alcoholic fatty liver 
or microbiota or microbiome or microflora or flora or intestinal or 
dysbiosis or inflamm*).mp.
28. 26 or 27
29. FERMENTATION/
30. Fermented Foods/
31. (monascus or monacolin or red yeast rice or Korean diet).mp.
32. (fermented or fermentation).mp.
33. 29 or 30 or 31 or 32
34. 28 and 33
35. 11 and 34
kombucha), as well as modern functional BFF (eg, func-
tional kimchi, red yeast rice) made with specific micro-
bial strains or additional beneficial ingredients. These 
plant-derived interventions may contain any concen-
tration of any types of live microorganisms, measured 
in colony forming units; BFF interventions without live 
microorganisms at time of consumption will also be 
included. Studies that use BFF as the sole intervention 
will be considered. Single compound extracts, BFFs 
mixed with non-fermented ingredients and BFFs as part 
of whole diet interventions will be excluded. Coffee, 
tea, chocolate, beer, wine and other high alcoholic 
beverages will not be included.
Participants in the sample will have been randomly allo-
cated into intervention (BFF) and placebo, no interven-
tion or active control groups.
Types of outcome measures
We will search for all published quantitative research 
based on one or more included outcome measures. 
Outcome measures will be related to the target condi-
tions, including, but not limited to changes in:
1. Weight as measured via waist circumference, body 
mass index and weight
2. Blood pressure (diastolic and systolic).
3. Lipid profile (fasting serum total cholesterol, high-den-
sity lipoprotein, low-density lipoprotein, triglycerides, 
free fatty acids)
4. Glucose metabolism (glycated haemoglobin, fasting 
plasma glucose, serum C-peptide, serum insulin).
5. Inflammatory markers (fasting serum high sensitivity 
C reactive protein, IL-6, IL-1B, tumour necrosis factor 
alpha).
6. Gut microbiota composition and metabolites (faecal 
metabolome, ribosomal RNA sequencing).
Other outcomes include liver markers (fasting serum 
aspartate aminotransferase, alanine aminotransferase), 
quality of life, mental health scales and adverse events.
Search methods for study identification
Data searches
The following four electronic databases will be searched 
from inception to present: Embase via Ovid, MEDLINE 
via Ovid, and Cochrane CENTRAL and Google Scholar 
(first 200 relevancy ranked results). Reference lists in 
identified articles and reviews, as well as studies that cited 
these articles, will be searched with Scopus. We will also 
search the grey literature via trials registries and confer-
ence papers. When a study has unreported data, authors 
will be contacted for further information.
Search strategy
The search strategy will combine subject heading terms 
and text words for BFF (eg, fermented food, fermen-
tation, red yeast rice) and subject heading terms and 
text words to capture MetS or T2DM (eg, MetS, obesity, 
hypertension, blood pressure, diabetes, pre-diabetes, 
hyperlipidaemia, microbiota, dysbiosis, inflammation/
inflammatory). To retrieve RCTs, the Cochrane Highly 
Sensitive Search Strategy for MEDLINE will be used. No 
date or language limits will be applied. The MEDLINE 
draft search strategy is included as box 1.
Selection of studies
One author (MC) and a clinical librarian (HB) will 
develop and execute a strategic search strategy following 
Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses guidelines. Two authors (MC and 
NL) will independently select articles to include by 
screening titles and abstracts, followed by full text 
assessment according to eligibility criteria. Duplicates 
will be removed and reasons for study exclusion will be 
recorded. Final eligibility will be determined through 
agreement between the two reviewers; resolution to 
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any disagreements will be achieved through discussion. 
Authors of trials will be contacted for clarification when 
necessary. All processes and data will be recorded using 
Covidence software.
data extraction and management
Using Covidence, two authors (MC and NL) will extract 
and manage the following data from eligible publica-
tions: study design, BFF type and dosage, duration of 
intervention, sample size, population, subjects’ char-
acteristics (age, sex, body mass index, symptom types), 
baseline metabolic biomarkers/gut microbiota profile, 
medication use, adverse events, treatment outcomes 
and other information. If reported data are insuffi-
cient, the authors of these studies will be contacted. 
Any disagreements will be resolved through discussion 
between the two authors.
risk of bias assessment
All included studies will be qualified using the Cochrane 
Collaboration's tool for risk of bias (ROB) assessment.14 
Domains will include random sequence generation, 
allocation sequence concealment, participant and 
outcome assessor blinding, incomplete outcome data, 
selective outcome reporting and other sources of bias. 
Each domain ROB will be classified as low, high or 
unclear risk.
data synthesis
If sufficient RCTs with robust heterogeneous pooled data 
for each outcome are identified, meta-analysis will be 
conducted. We will assume risk ratio-derived summary esti-
mates for dichotomous outcomes, and mean difference 
for continuous outcomes. Adoption of a random effect 
model will be considered for predicted clinical hetero-
geneity of BFF types. Expected inconsistencies across 
studies will require the use of I2 statistics and Galbraith 
plots14; substantial heterogeneity is considered at a 50% 
cut-off point. Depending on number of retrieved studies 
and their sample size, subgroup analyses will be stratified 
according to participant disease category, type of BFF and 
control intervention.
Covidence will be used to create a summary of findings 
table. If >10 studies are identified, potential publication 
and small sample bias will be assessed with funnel plots 
and Egger’s test.15 We will strive to identify possible causes 
of asymmetry, such as poor methodology or inappro-
priate effect measures.
If insufficient RCTs are available for meta-analysis, we 
will complete a narrative synthesis of included studies, 
summarising the study characteristics and BFF effec-
tiveness based on the specific results of the included 
studies. Subgroup analysis will also be conducted in this 
context.
Grading evidence quality
Quality of evidence for all included outcomes will be 
assessed using Grading of Recommendations Assess-
ment, Development and Evaluation working group 
methodology.16 Domains to be assessed: ROB, consis-
tency, precision, directness, publication bias and any 
additional points; classification will be into four levels 
(high, moderate, low or very low).
registration
To report this protocol, we used the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses reporting guideline extension for systematic review 
protocols (PRISMA-P).17 The PRISMA-P checklist for 
this protocol is available (online supplementary file 
1). Methodology is informed by the Cochrane Hand-
book for Systematic Reviews of Interventions. A stan-
dard version of the protocol has been registered with 
the International Prospective Register of Systematic 
Reviews http://www. crd. york. ac. uk/ PROSPERO/ 
display_ record. php? ID= CRD42018117766, and will be 
updated as necessary.
Ethics and dissemination
Formal ethical approval is not required as no individu-
alised data will be used; as such no privacy issues are 
apparent. Review findings will be disseminated through 
peer-reviewed publications (print and online) and confer-
ence presentations.
PAtIEnt And PublIC InvOlvEMEnt
No patients or public will be involved in this systematic 
review protocol.
dISCuSSIOn
As far as can be established, no systematic review of clin-
ical studies focused on BFF for MetS and T2DM has been 
conducted. When completed, this review will provide a 
summary of current evidence and identify further gaps 
in the research. The findings have the potential to influ-
ence clinical management of these increasingly preva-
lent non-communicable metabolic diseases, as well as 
contribute to the inclusion of BFFs in global food guides. 
The results of this review will also inform our interven-
tional trial design.
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